There are currently 53 active clinical trials seeking participants for Atopic Dermatitis research studies. The states with the highest number of trials for Atopic Dermatitis participants are California, Florida, Texas and Ontario.
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05882877
Recruiting
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
05/07/2025
Locations: Cahaba Dermatology and Skin Health Center, Birmingham, Alabama +532 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Atopic Dermatitis
NCT06863961
Recruiting
The purpose of this study is to assess the efficacy and safety of RO7790121 in participants with moderate to severe atopic dermatitis (AD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Dermatology Research Associate, Los Angeles, California +6 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
NCT06389136
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD. Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This stud... Read More
Gender:
ALL
Ages:
Between 18 years and 63 years
Trial Updated:
05/06/2025
Locations: Clinical Trials Institute - Northwest Arkansas /ID# 267290, Fayetteville, Arkansas +93 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
NCT06718101
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. The purpose of this study is to evaluate the clinical efficacy and safety of single therapies and/or combination therapies for moderate to severe AD through multiple substudies. This study will consist of multiple sub-studies, Sub-Study 1 will have a randomized, placebo controlled period 1 followed by a lutikizumab treatment period 2 enrolling 80 participants at a 1 to 1 ratio. In Sub-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Peak Dermatology Aesthetics and Wellness Fountain Hills /ID# 272550, Fountain Hills, Arizona +15 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
NCT06238817
Recruiting
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: Lynn Institute of the Ozarks, Little Rock, Arkansas +100 locations
Conditions: Atopic Dermatitis
Register for Updates
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
NCT03661866
Recruiting
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
All
Trial Updated:
05/02/2025
Locations: Clear Dermatology & Aesthetics Center/Investigative MD, Scottsdale, Arizona +62 locations
Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Alopecia Areata, Chronic Spontaneous Urticaria
Register for Updates
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06461897
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupilumab in pediatric participants with moderate to severe AD who are candidates for systemic therapy. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug... Read More
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
05/01/2025
Locations: Applied Research Center Of Arkansas /ID# 268547, Little Rock, Arkansas +115 locations
Conditions: Atopic Dermatitis
Register for Updates
Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)
NCT06945458
Recruiting
This is a study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered KT-621 in adult male and female patients with moderate to severe atopic dermatitis (AD).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/01/2025
Locations: Kymera Investigative Site, Birmingham, Alabama +11 locations
Conditions: Atopic Dermatitis
Register for Updates
Systems Biology of Early Atopy
NCT04798079
Recruiting
The goal of this study is to establish a birth cohort that collects prenatal and early life biosamples and environmental samples and rigorously phenotypes young children for food allergy and Atopic Dermatitis (AD) to identify prenatal and early life markers of high risk for food allergy and AD, as well as biological pathways (endotypes) that result in these conditions. Primary Objectives: * To study the role and interrelationships of established and novel clinical, environmental, biological, a... Read More
Gender:
ALL
Ages:
0 years and above
Trial Updated:
04/28/2025
Locations: Arkansas Children's Hospital, Little Rock, Arkansas +11 locations
Conditions: Allergic Diseases, Food Allergy, Atopic Dermatitis
Register for Updates
Topical Treatment for Atopic Dermatitis
NCT06244212
Recruiting
Medication adherence is a poorly studied phenomenon that challenges both patients and physicians. 50% of individuals with chronic disease are not adherent to their medication regimen. Within the United States, non-adherence to medical treatment leads to approximately $100 billion in hospital admission costs. While the issue of adherence is not limited to any particular field of medicine, non-adherence occurs in approximately one-third to one-half of dermatological patients. Non-adherence is of i... Read More
Gender:
ALL
Ages:
9 years and above
Trial Updated:
04/23/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Atopic Dermatitis
Register for Updates
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
NCT06504160
Recruiting
This is a Phase 1b, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S. hominis A9 (ShA9) topical application as a treatment for atopic dermatitis (AD). The trial will enroll adults and adolescents with atopic dermatitis who are culture positive for S. aureus colonization. The primary safety objective of this study is to compare the safety profile of ShA9 to placebo (vehicle) over 14 weeks of application, which inclu... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/22/2025
Locations: University of California, San Diego: Dermatology Clinical Trials Unit, San Diego, California +8 locations
Conditions: Atopic Dermatitis
Register for Updates
Seal, Stopping Eczema and Allergy Study
NCT03742414
Recruiting
This is a randomized, controlled trial designed for children who are have already developed atopic dermatitis (AD or eczema) by 12 weeks of age. The aim is to compare the effect of proactive sequential skin care, including the twice-daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone propionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
Gender:
ALL
Ages:
Between 1 week and 12 weeks
Trial Updated:
04/17/2025
Locations: Sean N. Parker Center for Allergy & Asthma Research at Stanford University, Palo Alto, California +4 locations
Conditions: Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis
Register for Updates